These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38450598)

  • 1. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
    J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma.
    Zhang G; Xiao Y; Liu H; Wu Y; Xue M; Li J
    Immunobiology; 2024 Sep; 229(5):152841. PubMed ID: 39096658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.
    Tambay V; Raymond VA; Voisin L; Meloche S; Bilodeau M
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Zhang G; Xiao Y; Tan J; Liu H; Fan W; Li J
    J Transl Med; 2024 Jun; 22(1):543. PubMed ID: 38844930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation.
    Liu Y; Miao Z; Yang Q
    Cell Biochem Biophys; 2024 Sep; 82(3):2037-2053. PubMed ID: 38789662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine.
    Shi X; Zhang Y; Wang Y; Wang J; Gao Y; Wang R; Wang L; Xiong M; Cao Y; Ou N; Liu Q; Ma H; Cai J; Chen H
    Cell Death Differ; 2024 Sep; 31(9):1219-1234. PubMed ID: 38867004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
    Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
    Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
    Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
    Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
    Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
    Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
    Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
    J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
    Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
    Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
    Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
    Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identify an innovative ferroptosis-related gene in hepatocellular carcinoma.
    Hu G; Huang X; Zhang B; Gao P; Wu W; Wang J
    J Clin Lab Anal; 2022 Sep; 36(9):e24632. PubMed ID: 35908779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.
    Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D
    J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
    Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
    J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0000808 promotes the development of non-small cell lung cancer by regulating glutamine metabolism via the miR-1827/SLC1A5 axis.
    Cai Y; Dong Z; Wang J
    World J Surg Oncol; 2022 Oct; 20(1):329. PubMed ID: 36192755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamine metabolic reprogramming in hepatocellular carcinoma.
    Ye Y; Yu B; Wang H; Yi F
    Front Mol Biosci; 2023; 10():1242059. PubMed ID: 37635935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.